Merck KGaA R&D Head: Biomarker Approach 'Further Validated' At ASCO

 
• By Sten Stovall

Luciano Rossetti says Germany's Merck is likely to partner M7824 bifunctional immunotherapy, and go solo with tepotinib.

Tumor marker
Merck KGaA is using biomarkers to select patients for testing Tepotinib and M7824. • Source: Shutterstock

More from Anticancer

More from Therapy Areas